Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Heart rate increases in liraglutide treated chronic heart failure patients : association with clinical parameters and adverse events. / Tougaard, Rasmus Stilling; Jorsal, Anders; Tarnow, Lise; Hansson, Nils Henrik; Kistorp, Caroline; Schou, Morten; Nielsen, Roni; Flyvbjerg, Allan; Videbaek, Lars; Mølgaard, Henning; Nielsen, Jens Cosedis; Gustafsson, Ida; Wiggers, Henrik.

In: Scandinavian Cardiovascular Journal, 15.04.2020, p. 1-6.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Tougaard, Rasmus Stilling ; Jorsal, Anders ; Tarnow, Lise ; Hansson, Nils Henrik ; Kistorp, Caroline ; Schou, Morten ; Nielsen, Roni ; Flyvbjerg, Allan ; Videbaek, Lars ; Mølgaard, Henning ; Nielsen, Jens Cosedis ; Gustafsson, Ida ; Wiggers, Henrik. / Heart rate increases in liraglutide treated chronic heart failure patients : association with clinical parameters and adverse events. In: Scandinavian Cardiovascular Journal. 2020 ; pp. 1-6.

Bibtex

@article{f02afeaa62ac45578faff485fffac813,
title = "Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events",
abstract = "Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.",
author = "Tougaard, {Rasmus Stilling} and Anders Jorsal and Lise Tarnow and Hansson, {Nils Henrik} and Caroline Kistorp and Morten Schou and Roni Nielsen and Allan Flyvbjerg and Lars Videbaek and Henning M{\o}lgaard and Nielsen, {Jens Cosedis} and Ida Gustafsson and Henrik Wiggers",
year = "2020",
month = apr,
day = "15",
doi = "10.1080/14017431.2020.1751873",
language = "English",
pages = "1--6",
journal = "Scandinavian Cardiovascular Journal",
issn = "1401-7431",
publisher = "Taylor & Francis ",

}

RIS

TY - JOUR

T1 - Heart rate increases in liraglutide treated chronic heart failure patients

T2 - association with clinical parameters and adverse events

AU - Tougaard, Rasmus Stilling

AU - Jorsal, Anders

AU - Tarnow, Lise

AU - Hansson, Nils Henrik

AU - Kistorp, Caroline

AU - Schou, Morten

AU - Nielsen, Roni

AU - Flyvbjerg, Allan

AU - Videbaek, Lars

AU - Mølgaard, Henning

AU - Nielsen, Jens Cosedis

AU - Gustafsson, Ida

AU - Wiggers, Henrik

PY - 2020/4/15

Y1 - 2020/4/15

N2 - Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

AB - Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

U2 - 10.1080/14017431.2020.1751873

DO - 10.1080/14017431.2020.1751873

M3 - Journal article

C2 - 32292074

SP - 1

EP - 6

JO - Scandinavian Cardiovascular Journal

JF - Scandinavian Cardiovascular Journal

SN - 1401-7431

ER -